[go: up one dir, main page]

Ovarian Neoplasms

"Ovarian Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

expand / collapse MeSH information
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.


expand / collapse Publications
This graph shows the total number of publications written about "Ovarian Neoplasms" by people in this website by year, and whether "Ovarian Neoplasms" was a major or minor topic of these publications.
Below are the most recent publications written about "Ovarian Neoplasms" by people in Profiles.
  1. Mechanistic role of FN1 in LAIR-1 mediated downregulation of ovarian cancer cell proliferation. BMC Cancer. 2025 Feb 25; 25(1):339.
    View in: PubMed
  2. Surgical Management of Gynecologic Cancers. Hematol Oncol Clin North Am. 2025 Feb; 39(1):67-87.
    View in: PubMed
  3. Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers. Cancer Discov. 2025 Jan 13; 15(1):105-118.
    View in: PubMed
  4. Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1+CD8+ T Cells in Metastatic Ovarian Cancer. Clin Cancer Res. 2025 Jan 06; 31(1):164-180.
    View in: PubMed
  5. Commentary: Ovarian Cancer: Path to Effective Treatments. Crit Rev Immunol. 2025; 45(1):93-99.
    View in: PubMed
  6. Real-world duration of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer in the United States: the CHAR1ZMA study. Int J Gynecol Cancer. 2025 Feb; 35(2):100044.
    View in: PubMed
  7. SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer. Clin Cancer Res. 2024 Dec 16; 30(24):5593-5600.
    View in: PubMed
  8. Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity. Sci Adv. 2024 Dec 06; 10(49):eadk4851.
    View in: PubMed
  9. Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma. Cancer Res Commun. 2024 12 01; 4(12):3165-3179.
    View in: PubMed
  10. Loss of XIST lncRNA unlocks stemness and cellular plasticity in ovarian cancer. Proc Natl Acad Sci U S A. 2024 Nov 19; 121(47):e2418096121.
    View in: PubMed